Context Therapeutics (CNTX) Assets Average (2021 - 2026)

Context Therapeutics has disclosed Assets Average across 6 years of filings, most recently posting $63.7 million for Q1 2026.

• Assets Average for Q1 2026 came in at $63.7 million, down 33.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.7 million (down 33.36% YoY), and the FY2025 annual result was $83.3 million, up 45.92% from the prior year.
• Assets Average came in at $63.7 million for Q1 2026 at Context Therapeutics, down from $73.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $95.5 million in Q1 2025 to a low of $13.6 million in Q1 2024.
• The 5-year median for Assets Average is $49.2 million (2022), against an average of $56.0 million.
• Across the five-year window, Assets Average sank 61.23% in 2024 and surged 604.76% in 2025, its largest moves.
• Context Therapeutics' Assets Average stood at $40.0 million in 2022, then plunged by 51.22% to $19.5 million in 2023, then jumped by 372.34% to $92.2 million in 2024, then decreased by 19.91% to $73.9 million in 2025, then dropped by 13.79% to $63.7 million in 2026.
• The last three Assets Average figures came in at $63.7 million (Q1 2026), $73.9 million (Q4 2025), and $83.2 million (Q3 2025), per Business Quant data.